

PHARMACEUTICAL 2022



## GERON CORP Rank 301 of 466







PHARMACEUTICAL 2022

**GERON CORP** 

Rank 301 of 466

## **≬**geron

The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 19% points. The greatest weakness of GERON CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 62%, being 16% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	187,206
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	45,521
Liabilities, Non-Current	54,097
Other Assets	38,178
Other Compr. Net Income	-251
Other Expenses	3,740
Other Liabilities	0
Other Net Income	1,627
Other Revenues	1,393
Property and Equipment	650
Research and Development	85,727
Selling, General and Administrative Expense	29,665

Output Variable	Value in 1000 USD
Assets	226,034
Liabilities	99,618
Expenses	119,132
Revenues	1,393
Stockholders Equity	126,416
Net Income	-116,112
Comprehensive Net Income	-116,238
Economic Capital Ratio	62%

